Management of Acute Pulmonary Embolism in Patients Receiving Apixaban

1. Immediate Risk Stratification

• High‑risk (massive) PE is defined by sustained systolic blood pressure < 90 mm Hg for ≥15 min, need for vasopressors, or shock. European Society of Cardiology (ESC) guideline, Class I, Level B 1.
• Intermediate‑risk (sub‑massive) PE occurs in hemodynamically stable patients who have right‑ventricular (RV) dysfunction on imaging or elevated cardiac biomarkers. ESC guideline, Class II, Level B 2.
• Low‑risk PE is present when patients are hemodynamically stable and have no RV dysfunction or biomarker elevation. ESC guideline, Class II, Level B 2.

2. Management of High‑Risk PE

• Stop apixaban immediately and initiate a weight‑adjusted unfractionated heparin (UFH) bolus before any other therapy. ESC guideline, Class I, Level C 3.
• Administer systemic thrombolysis as rescue therapy (e.g., alteplase). ESC guideline, Class I, Level B 1.
• If thrombolysis is contraindicated or fails, perform surgical pulmonary embolectomy. ESC guideline, Class I, Level C 3.
• Percutaneous catheter‑directed therapy is an alternative when thrombolysis is unsuitable. ESC guideline, Class IIa, Level C 3.
• For refractory circulatory collapse, consider veno‑arterial ECMO combined with surgery or catheter‑directed therapy. ESC guideline, Class IIb, Level C 3.
• Hemodynamic support with norepinephrine and/or dobutamine should be provided as needed. ESC guideline, Class IIa, Level C 3.

3. Management of Intermediate‑ and Low‑Risk PE

• Verify apixaban dosing and patient adherence before assuming therapeutic failure. ESC guideline, Class II, Level B 4.
• Identify contraindications to NOACs (e.g., severe renal impairment CrCl < 30 mL/min, antiphospholipid antibody syndrome). ESC guideline, Class II, Level B 1.
• When dosing is correct and adherence confirmed, switch to parenteral anticoagulation (LMWH or fondaparinux preferred over UFH). ESC guideline, Class IIa, Level C 3.
• Consider transition to a vitamin‑K antagonist (warfarin) with parenteral overlap until INR 2.0–3.0 (target ≈ 2.5). ESC guideline, Class IIa, Level B 4.
• Do not increase the apixaban dose; supra‑therapeutic NOAC dosing lacks supporting evidence.

If the patient deteriorates:

• Rescue systemic thrombolysis should be given (Class I, Level B). ESC guideline 1.
• Surgical embolectomy or catheter‑directed therapy are alternative options (Class IIa, Level C). ESC guideline 3.

4. Investigation of Underlying Causes

• Assess adherence and timing of the last apixaban dose (anticoagulant effect persists ≈ 24 h). ESC guideline 4.
• Check renal function; severe impairment (eGFR < 30 mL/min) contraindicates NOACs. ESC guideline 1.
• Screen for antiphospholipid antibody syndrome; if present, switch to VKA. ESC guideline 1.
• Evaluate for occult malignancy, as cancer‑associated thrombosis often warrants LMWH rather than oral anticoagulants. Thorax article 5.

5. Inferior Vena Cava (IVC) Filter Considerations

• IVC filters may be placed in patients with (a) absolute contraindication to anticoagulation or (b) recurrent PE despite documented therapeutic anticoagulation. ESC guideline, Class IIa, Level C 3.
• Routine use of IVC filters is discouraged (Class III, Level A). ESC guideline 1.

6. Long‑Term Anticoagulation Strategy

• Recurrent VTE (≥ 1 prior PE/DVT) not linked to a transient risk factor → indefinite anticoagulation. ESC guideline, Class I, Level A 2.
• Diagnosed antiphospholipid syndrome → lifelong VKA therapy (NOACs contraindicated). ESC guideline 1.
• Identified malignancy → LMWH is the preferred long‑term agent. Thorax article 5.
• Regular reassessment of drug tolerance, adherence, hepatic/renal function, and bleeding risk is required. ESC guideline 4.

7. Follow‑Up and Monitoring

• Schedule routine clinical review 3–6 months after the acute event to assess treatment response and recurrence risk. ESC guideline 1.
• Screen for chronic thromboembolic pulmonary hypertension (CTEPH) in patients with persistent symptoms and perfusion defects beyond 3 months. ESC guideline 2.
• Implement an integrated care pathway to ensure seamless transition from inpatient to outpatient management. ESC guideline 4.

8. Common Pitfalls to Avoid

• Do not continue apixaban at the same dose after a breakthrough PE; this indicates treatment failure. ESC guideline 1.
• Avoid NOACs in severe renal impairment, antiphospholipid syndrome, or pregnancy. ESC guideline 2.
• Reserve systemic thrombolysis for high‑risk or rescue situations; it is not indicated for routine use in intermediate/low‑risk PE. ESC guideline, Class III, Level B 3.
• Never rely solely on patient self‑report for anticoagulation adequacy; verify dosing, timing, and adherence objectively. ESC guideline 4.
• Promptly switch to parenteral anticoagulation when NOAC failure is suspected; delays increase morbidity. ESC guideline 3.

Acute Pulmonary Embolism Management Guidelines (ESC)

1. Risk Stratification

• Patients are classified by hemodynamic status:
  (European Society of Cardiology, Class I, Level C) 6

2. Immediate Anticoagulation (All Risk Categories)

• Unfractionated heparin (weight‑adjusted bolus) should be started without delay in every patient with suspected PE while diagnostic work‑up proceeds.
  (ESC, Class I, Level C) 6

3. High‑Risk PE (Hemodynamically Unstable)

3.1 First‑Line Reperfusion

• Systemic thrombolysis is the recommended first‑line therapy (Class I, Level B).
  (ESC) 6

3.2 Hemodynamic Support

• Norepinephrine and/or dobutamine may be used to support circulation (Class IIa, Level C).
  (ESC) 6

3.3 Alternatives When Thrombolysis Fails or Is Contra‑indicated

4. Intermediate‑ and Low‑Risk PE

4.1 Anticoagulation Strategy

• Parenteral anticoagulation: Low‑molecular‑weight heparin (LMWH) or fondaparinux is preferred over UFH (Class I, Level A).
  (ESC) 6
• Oral anticoagulation: Direct oral anticoagulants (NOACs – apixaban, dabigatran, edoxaban, rivaroxaban) are preferred to vitamin‑K antagonists (VKA) in eligible patients (Class I, Level A).
  (ESC) 6
• If a VKA is used: Overlap with parenteral anticoagulation until the INR reaches 2.0–3.0 (target ≈ 2.5) (Class I, Level A).
  (ESC) 6

4.2 Contra‑indications to NOACs

• Severe renal impairment, pregnancy/lactation, and antiphospholipid antibody syndrome are absolute contraindications to NOACs (Class III, Level C); VKAs remain the oral option.
  (ESC) 6

4.3 Rescue Therapy for Clinical Deterioration

• Rescue systemic thrombolysis is recommended if a patient deteriorates hemodynamically while on anticoagulation (Class I, Level B).
  (ESC) 6
• If thrombolysis is unsuitable, surgical embolectomy or catheter‑directed therapy should be considered (Class IIa, Level C).
  (ESC) 6
• Routine systemic thrombolysis is NOT recommended for intermediate‑ or low‑risk PE (Class III, Level B).
  (ESC) 6

5. Inferior Vena Cava (IVC) Filters

• Consider IVC filters in patients with absolute contraindications to anticoagulation (Class IIa, Level C).
  (ESC) 6
• Consider IVC filters for recurrent PE despite therapeutic anticoagulation (Class IIa, Level C).
  (ESC) 6
• Routine use of IVC filters is NOT recommended (Class III, Level A).
  (ESC) 6

6. Early Discharge & Outpatient Management

• Select low‑risk PE patients may be discharged early provided reliable outpatient follow‑up and anticoagulation can be ensured (Class IIa, Level A).
  (ESC) 6

7. Multidisciplinary Pulmonary Embolism Response Teams (PERT)

• Establishment of PERTs is encouraged for managing high‑risk and selected intermediate‑risk PE, integrating cardiology, pulmonology, hematology, vascular medicine, intensive care, cardiothoracic surgery, and interventional radiology.
  (ESC) 7

8. Duration of Anticoagulation

• Minimum treatment duration is 3 months for all PE patients.
  (ESC) 8
• Discontinue oral anticoagulation after 3 months if the first PE was provoked by a major transient/reversible risk factor.
  (ESC) 8
• Continue anticoagulation indefinitely for patients with recurrent VTE (≥ 1 prior PE/DVT) not related to a transient risk factor.
  (ESC) 8

9. Common Pitfalls (What NOT to Do)

• Do not withhold anticoagulation while awaiting diagnostic confirmation in patients with high or intermediate clinical probability (increases VTE events and mortality).
  (ESC, Class III) 9
• Do not rely on a normal D‑dimer to exclude PE in high‑probability patients (Class III).
  (ESC) 8
• Do not use NOACs in severe renal impairment, pregnancy, lactation, or antiphospholipid syndrome.
  (ESC) 6
• Do not routinely administer systemic thrombolysis in intermediate‑ or low‑risk PE; reserve it for high‑risk or rescue situations.
  (ESC) 6